



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/806,125  
Filed: 3/28/2001  
1<sup>st</sup> Inventor: MATSUTANI, Eisuya  
For: Agent that retards the transformation of  
hormone-dependent cancer to non-hormone  
dependent cancer  
Atty. Dkt. No. 2556 USOP

Art Unit: 1642  
Examiner: Rawlings, S.  
Allowed:  
Batch:  
Paper No.:

#  
151D  
RECEIVED  
JUN 04 2003  
TECH CENTER 1600/2900

Response to Notice to Comply with Sequence Listing Requirements

MAIL STOP SEQUENCE  
Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

Sir:

In response to the Notice to Comply mailed May 23, 2003, Applicants respectfully submit, along with a copy of the Notice, a substitute written Sequence Listing and a replacement DOS Text CRF Sequence Listing file "2556SEQ.txt" on the enclosed 3.5" IBM PC/AT computer disk.

The undersigned hereby certifies that the CRF and the written Sequence Listing are the same in content. The Sequence Listing contains no new matter.

Respectfully submitted,

Dated: May 27, 2003


(847)383-3372  
(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

06/09/2003 KDOWNING 00000002 500799 09806125  
01 FC:1251 110.00 CH

**Notice to Comply**



Application No.

09/806,125

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)

MATSUTANI ET AL.

Art Unit

1642

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600


**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

J. Rawlings



Re-run

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/806,125C  
Source: 1600  
Date Processed by STIC: 5/8/2003

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)

2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

3. Hand Carry directly to:

U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name,  
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202

Or

U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,  
2011 South Clark Place, Arlington, VA 22202

4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,  
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 04/24/2003

See page 2



## RAW SEQUENCE LISTING

DATE: 05/08/2003

PATENT APPLICATION: US/09/806,125C

TIME: 15:01:09

Input Set : A:\EP.txt

Output Set: N:\CRF4\05082003\I806125C.raw

File:///C:/C:\Program Files\Internet Explorer\VerI806125C.htm

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/806,125C

DATE: 05/08/2003  
TIME: 15:01:09

Input Set : A:\EP.txt  
Output Set: N:\CRF4\05082003\I806125C.raw

64 <223> OTHER INFORMATION: DLeu, DAla, DTrp, DSer(tBut), D2Nal, DHis(ImBzl)  
66 <220> FEATURE:  
67 <221> NAME/KEY: MOD\_RES  
68 <222> LOCATION: (9)..(9)  
69 <223> OTHER INFORMATION: Pro or Pro-NH-C2H5  
71 <220> FEATURE:  
72 <221> NAME/KEY: MOD\_RES  
73 <222> LOCATION: (10)..(10)  
74 <223> OTHER INFORMATION: Gly-NH2 or nothing  
77 <400> SEQUENCE: 2  
W--> 79 Pro His Trp Ser Tyr Xaa Leu Arg Xaa Xaa  
80 1 5 10  
82 <210> SEQ ID NO: 3  
83 <211> LENGTH: 11  
84 <212> TYPE: PRT  
85 <213> ORGANISM: Artificial Sequence  
87 <220> FEATURE:  
88 <223> OTHER INFORMATION: synthetic LH-RH peptide derivative  
90 <220> FEATURE:  
91 <221> NAME/KEY: MOD\_RES  
92 <222> LOCATION: (1)..(1)  
93 <223> OTHER INFORMATION: N(4H2-furoyl)Gly, NAC  
96 <220> FEATURE:  
97 <221> NAME/KEY: MOD\_RES  
98 <222> LOCATION: (2)..(2)  
99 <223> OTHER INFORMATION: D2Nal  
102 <220> FEATURE:  
103 <221> NAME/KEY: MOD\_RES  
104 <222> LOCATION: (3)..(3)  
105 <223> OTHER INFORMATION: D4ClPhe  
108 <220> FEATURE:  
109 <221> NAME/KEY: MOD\_RES  
110 <222> LOCATION: (4)..(4)  
111 <223> OTHER INFORMATION: D3Pal  
115 <220> FEATURE:  
116 <221> NAME/KEY: MOD\_RES  
117 <222> LOCATION: (6)..(6)  
118 <223> OTHER INFORMATION: NMeTyr, Tyr, Aph(Atz), NMeAph(Atz)  
121 <220> FEATURE:  
122 <221> NAME/KEY: MOD\_RES  
123 <222> LOCATION: (7)..(7)  
124 <223> OTHER INFORMATION: DLys(Nisp), DCit, DLys(AzaglyNic), DLys(AzaglyFur), DhArg  
(Atz), D  
125 hC  
128 <220> FEATURE:  
129 <221> NAME/KEY: MOD\_RES  
130 <222> LOCATION: (9)..(9)  
131 <223> OTHER INFORMATION: Lys(Nisp), Arg, hArg(Et2)  
134 <400> SEQUENCE: 3  
W--> 136 Xaa Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa

ALL Xaa Location  
must be explained in a  
Feature 1

RAW SEQUENCE LISTING  
 PATENT APPLICATION: US/09/806,125C

DATE: 05/08/2003  
 TIME: 15:01:09

Input Set : A:\EP.txt  
 Output Set: N:\CRF4\05082003\I806125C.raw

```

137 1          5          10
139 <210> SEQ ID NO: 4
140 <211> LENGTH: 6
141 <212> TYPE: PRT
142 <213> ORGANISM: Artificial Sequence
144 <220> FEATURE:
145 <223> OTHER INFORMATION: synthetic kinase consensus target peptide
147 <400> SEQUENCE: 4
149 His Arg Asp Leu Ala Ala
150 1          5
152 <210> SEQ ID NO: 5
153 <211> LENGTH: 5
154 <212> TYPE: PRT
155 <213> ORGANISM: Artificial Sequence
157 <220> FEATURE:
158 <223> OTHER INFORMATION: synthetic kinase consensus target peptide
160 <400> SEQUENCE: 5
162 Ser Asp Val Trp Ser
163 1          5
165 <210> SEQ ID NO: 6
166 <211> LENGTH: 16
167 <212> TYPE: DNA
168 <213> ORGANISM: Artificial Sequence
171 <220> FEATURE:
172 <223> OTHER INFORMATION: primer
174 <220> FEATURE:
175 <221> NAME/KEY: misc_feature
176 <222> LOCATION: (4)..(4)
177 <223> OTHER INFORMATION: C or A
180 <220> FEATURE:
181 <221> NAME/KEY: misc_feature
182 <222> LOCATION: (3)..(3)
183 <223> OTHER INFORMATION: C or T
186 <220> FEATURE:
187 <221> NAME/KEY: misc_feature
188 <222> LOCATION: (9)..(10)
189 <223> OTHER INFORMATION: C or T
192 <400> SEQUENCE: 6
W--> 193 canngggann ggcgc
196 <210> SEQ ID NO: 7
197 <211> LENGTH: 16
198 <212> TYPE: DNA
199 <213> ORGANISM: Artificial Sequence
201 <220> FEATURE:
202 <223> OTHER INFORMATION: primer
204 <220> FEATURE:
205 <221> NAME/KEY: misc_feature
206 <222> LOCATION: (2)..(2)
207 <223> OTHER INFORMATION: a or g

```

16

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/806,125C

DATE: 05/08/2003

TIME: 15:01:09

Input Set : A:\EP.txt

Output Set: N:\CRF4\05082003\I806125C.raw

210 <220> FEATURE:  
 211 <221> NAME/KEY: misc\_feature  
 212 <222> LOCATION: (8)..(8)  
 213 <223> OTHER INFORMATION: c or a  
 216 <220> FEATURE:  
 217 <221> NAME/KEY: misc\_feature  
 218 <222> LOCATION: (11)..(11)  
 219 <223> OTHER INFORMATION: g or a  
 222 <220> FEATURE:  
 223 <221> NAME/KEY: misc\_feature  
 224 <222> LOCATION: (14)..(14)  
 225 <223> OTHER INFORMATION: a or g  
 228 <400> SEQUENCE: 7  
 W--> 229 anctccanac ntcnct  
 232 <210> SEQ ID NO: 8  
 233 <211> LENGTH: 17  
 234 <212> TYPE: DNA  
 235 <213> ORGANISM: Artificial Sequence  
 237 <220> FEATURE:  
 238 <223> OTHER INFORMATION: primer  
 240 <220> FEATURE:  
 241 <221> NAME/KEY: misc\_feature  
 242 <222> LOCATION: (3)..(3)  
 243 <223> OTHER INFORMATION: c or t  
 246 <220> FEATURE:  
 247 <221> NAME/KEY: misc\_feature  
 248 <222> LOCATION: (4)..(4)  
 249 <223> OTHER INFORMATION: c or a  
 252 <220> FEATURE:  
 253 <221> NAME/KEY: misc\_feature  
 254 <222> LOCATION: (6)..(6)  
 255 <223> OTHER INFORMATION: g or a  
 258 <220> FEATURE:  
 259 <221> NAME/KEY: misc\_feature  
 260 <222> LOCATION: (10)..(10)  
 261 <223> OTHER INFORMATION: c or t  
 264 <220> FEATURE:  
 265 <221> NAME/KEY: misc\_feature  
 266 <222> LOCATION: (12)..(12)  
 267 <223> OTHER INFORMATION: g or t  
 270 <220> FEATURE:  
 271 <221> NAME/KEY: misc\_feature  
 272 <222> LOCATION: (15)..(15)  
 273 <223> OTHER INFORMATION: a or t  
 276 <400> SEQUENCE: 8  
 W--> 277 canngngacn tngcngc  
 280 <210> SEQ ID NO: 9  
 281 <211> LENGTH: 16  
 282 <212> TYPE: DNA

16

17

RAW SEQUENCE LISTING  
 PATENT APPLICATION: US/09/806,125C

DATE: 05/08/2003  
 TIME: 15:01:09

Input Set : A:\EP.txt  
 Output Set: N:\CRF4\05082003\I806125C.raw

283 <213> ORGANISM: Artificial Sequence  
 285 <220> FEATURE:  
 286 <223> OTHER INFORMATION: primer  
 288 <220> FEATURE:  
 289 <221> NAME/KEY: misc\_feature  
 290 <222> LOCATION: (2)..(2)  
 291 <223> OTHER INFORMATION: a or g  
 294 <220> FEATURE:  
 295 <221> NAME/KEY: misc\_feature  
 296 <222> LOCATION: (8)..(8)  
 297 <223> OTHER INFORMATION: a or c  
 300 <220> FEATURE:  
 301 <221> NAME/KEY: misc\_feature  
 302 <222> LOCATION: (14)..(14)  
 303 <223> OTHER INFORMATION: a or c  
 306 <400> SEQUENCE: 9  
 W--> 307 anctccanac gtcnga  
 310 <210> SEQ ID NO: 10  
 311 <211> LENGTH: 17  
 312 <212> TYPE: DNA  
 313 <213> ORGANISM: Artificial Sequence  
 315 <220> FEATURE:  
 316 <223> OTHER INFORMATION: primer  
 318 <220> FEATURE:  
 319 <221> NAME/KEY: misc\_feature  
 320 <222> LOCATION: (3)..(3)  
 321 <223> OTHER INFORMATION: c or t  
 324 <220> FEATURE:  
 325 <221> NAME/KEY: misc\_feature  
 326 <222> LOCATION: (4)..(4)  
 327 <223> OTHER INFORMATION: c or a  
 330 <220> FEATURE:  
 331 <221> NAME/KEY: misc\_feature  
 332 <222> LOCATION: (6)..(6)  
 333 <223> OTHER INFORMATION: g or a  
 336 <220> FEATURE:  
 337 <221> NAME/KEY: misc\_feature  
 338 <222> LOCATION: (10)..(10)  
 339 <223> OTHER INFORMATION: c or t  
 342 <220> FEATURE:  
 343 <221> NAME/KEY: misc\_feature  
 344 <222> LOCATION: (15)..(15)  
 345 <223> OTHER INFORMATION: a or g  
 348 <400> SEQUENCE: 10  
 W--> 349 canngngacn tggcngc  
 352 <210> SEQ ID NO: 11  
 353 <211> LENGTH: 16  
 354 <212> TYPE: DNA  
 355 <213> ORGANISM: Artificial Sequence

16

17





VERIFICATION SUMMARY

DATE: 05/08/2003

PATENT APPLICATION: US/09/806,125C

TIME: 15:01:10

Input Set : A:\EP.txt

Output Set: N:\CRF4\05082003\I806125C.raw

L:50 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0  
 L:79 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0  
 L:136 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0  
 L:193 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0  
 L:229 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0  
 L:277 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0  
 L:307 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0  
 L:349 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0  
 L:385 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0